2026 · 2nd Quarter (Apr 1 - June 30)
Filed by FORBES-TATE.
Open official filingSource-reported fields
Literal source text
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Literal federal measure citations: H.R. 5316, H.R. 6509, S. 3794
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Literal federal measure citations: H.R. 4231, S. 1973, H.R. 5316, H.R. 6509, S. 3794
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
